Apoptosis is one cause of thrombocytopenia in patients with high-altitude polycythemia

• Published in: Platelets
• Main Authors: Zhuoya Wang, Noryung Tenzing, Qiying Xu, Huifang Liu, Yi Ye, Yi Wen, Tana Wuren, Sen Cui
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2023-12-01
• Subjects: high-altitude polycythemia; platelet apoptosis; thrombocytopenia; thrombosis
• Online Access: http://dx.doi.org/10.1080/09537104.2022.2157381

High-altitude polycythemia (HAPC) can occur in individuals who are intolerant to high-altitude hypoxia. In patients with HAPC, erythrocytosis is often accompanied by a decrease in platelet count. Chronic hypoxia can increase the incidence of arteriovenous thrombosis and the risk of bleeding during antithrombotic treatment due to thrombocytopenia; therefore, understanding the cause of thrombocytopenia can reduce the risk of treatment-related bleeding. In this study, we examined platelet production and apoptosis to understand the cause of thrombocytopenia in patients with HAPC. The classification of myeloid-derived megakaryocytes (MKs) in HAPC patients was mainly granular MKs rather than mature MKs, suggesting impaired differentiation and maturation. However, the total number of MKs and newly generated reticulated platelets in the peripheral blood increased, indicating sufficient platelet generation in HAPC thrombocytopenia. Increased platelet apoptosis may be one of the causes of thrombocytopenia. Platelet activation and GP1bα pathway activation induced by thrombin and von Willebrand factor can lead to platelet apoptosis. Platelet production was not reduced in patients with HAPC, whereas platelet apoptosis was associated with thrombocytopenia. These findings provide a rationale for considering the bleeding risk in HAPC patient while treating thrombotic diseases.